AARD Lead Plaintiff Deadline is Quickly Approaching - Robbins LLP Urges Aardvark Therapeutics, Inc. Stockholders to Contact the Firm for Information About Leading the Class Action
Robbins LLP issued a lead-plaintiff deadline reminder for a securities class action against Aardvark Therapeutics covering purchasers in the February 13, 2025 IPO and between February 13, 2025 and May 14, 2026. The complaint alleges Aardvark misled investors about ARD-101's safety and commercial prospects; the release recaps the February 2026 HERO trial pause (-56.2% stock drop) and May 2026 full FDA clinical hold (-32.1% drop).
Key figures
- Class period
- February 13, 2025 to May 14, 2026
- Stock drop 1
- -$7.02 (-56.2%) to $5.47 on March 2, 2026
- Stock drop 2
- -$2.16 (-32.1%) to $4.57 on May 15, 2026
- Lead plaintiff deadline
- October 13, 2026
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.